Nexalin Technology (NXL) Net Cash Flow Growth (1y) (2022 - 2026)
Nexalin Technology (NXL) Net Cash Flow Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | -562.77% |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 2,827.78% |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | -395.56% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 168.38% |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | -103.49% |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | -114.85% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | -215.59% |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | -54.17% |
| 10 | Nexalin Technology | 6.98 Mn | 5.97 Mn | 8,897.00 | 95.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95.80% |
| Mar 31, 2026 | 1,063.37% |
| Dec 31, 2025 | -86.88% |
| Sep 30, 2025 | 103.00% |
| Jun 30, 2025 | -1,698.83% |
| Mar 31, 2025 | 239.94% |
| Dec 31, 2024 | 125.31% |
| Sep 30, 2024 | -4,174.46% |
| Jun 30, 2024 | 433.01% |
| Mar 31, 2024 | -378.07% |
| Dec 31, 2023 | 124.14% |
| Sep 30, 2023 | -98.29% |
| Jun 30, 2023 | 133.93% |
| Mar 31, 2023 | 106.01% |
| Dec 31, 2022 | -272.54% |